Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis:...
According to 52-week study results presented at the annual meeting, subcutaneous secukinumab (SEC) provided sustained inhibition of radiographic progression in patients with active psoriatic arthritis.
Research Finds Low Immunogenicity with Secukinumab in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Results from a new study presented at the 2018 annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals indicated that treatment with secukinumab (SEC) was associated with a low incidence of immunogenicity over 52 weeks in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS), similar to results seen in patients with plaque psoriasis.
Online resource help increase awareness in at-risk patient populations, according to results from a new study presented by the researchers at the 2018 annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals.
Children with Arthritis and Adverse Childhood Experiences Have Higher Rates of Depression, Anxiety, and...
Children with juvenile idiopathic arthritis (JIA) have a higher prevalence of adverse childhood experiences, according to new research presented at the annual meeting. In addition, children with JIA who have adverse childhood experiences are more likely to experience depression, anxiety, and physical impairment.
According to research presented at the annual meeting, patients with gout who fail to reach a serum urate target of 6 mg/dL have a higher risk for mortality. The presenters encouraged rheumatologists to “treat to target” in patients with gout in order to improve chances of survival.
At its annual meeting, the American College of Rheumatology (ACR) presented a draft of a clinical practice guideline to help rheumatologists and obstetricians/gynecologists manage the reproductive health of patients with rheumatic disease.